These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 30700202)

  • 1. Adherence to Disease-Modifying Therapies at a Multiple Sclerosis Clinic: The Role of the Specialty Pharmacist.
    Banks AM; Peter ME; Holder GM; Jolly JA; Markley BM; Zuckerman SL; Choi L; Nwosu S; Zuckerman AD
    J Pharm Pract; 2020 Oct; 33(5):605-611. PubMed ID: 30700202
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adherence to oral oncolytics filled through an internal health-system specialty pharmacy compared with external specialty pharmacies.
    Academia EC; Mejías-De Jesús CM; Stevens JS; Jia LY; Yankama T; Patel C; Lee J
    J Manag Care Spec Pharm; 2021 Oct; 27(10):1438-1446. PubMed ID: 34595953
    [No Abstract]   [Full Text] [Related]  

  • 3. Compliance to fingolimod and other disease modifying treatments in multiple sclerosis patients, a retrospective cohort study.
    Agashivala N; Wu N; Abouzaid S; Wu Y; Kim E; Boulanger L; Brandes DW
    BMC Neurol; 2013 Oct; 13():138. PubMed ID: 24093542
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adherence and persistence to self-administered disease-modifying therapies in patients with multiple sclerosis: A multisite analysis.
    Zuckerman AD; DeClercq J; Simonson D; Zagel AL; Turco E; Banks A; Wawrzyniak J; Rightmier E; Blevins A; Choi L
    Mult Scler Relat Disord; 2023 Jul; 75():104738. PubMed ID: 37182475
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inclusion in limited distribution drug network reduces time to dalfampridine access in patients with multiple sclerosis at a health-system specialty pharmacy.
    Peter ME; Markley B; DeClercq J; Choi L; Givens G; Zuckerman AD; Banks A
    J Manag Care Spec Pharm; 2021 Feb; 27(2):256-262. PubMed ID: 33506731
    [No Abstract]   [Full Text] [Related]  

  • 6. A Comparison of Pharmacy Dispensing Channel Use and Adherence to Specialty Drugs Among Medicare Part D Beneficiaries.
    Kale HP; Patel AM; Carroll NV
    J Manag Care Spec Pharm; 2018 Apr; 24(4):317-326. PubMed ID: 29578855
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between multiple sclerosis disease severity and adherence to disease-modifying therapies.
    Burkhard A; Toliver J; Rascati K
    J Manag Care Spec Pharm; 2021 Jul; 27(7):915-923. PubMed ID: 34185555
    [No Abstract]   [Full Text] [Related]  

  • 8. Rheumatoid arthritis medication adherence in a health system specialty pharmacy.
    Berger N; Peter M; DeClercq J; Choi L; Zuckerman AD
    Am J Manag Care; 2020 Dec; 26(12):e380-e387. PubMed ID: 33315331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Persistence with and adherence to fingolimod compared with other disease-modifying therapies for the treatment of multiple sclerosis: a retrospective US claims database analysis.
    Bergvall N; Petrilla AA; Karkare SU; Lahoz R; Agashivala N; Pradhan A; Capkun G; Makin C; McGuiness CB; Korn JR
    J Med Econ; 2014 Oct; 17(10):696-707. PubMed ID: 25019581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of rates of adherence to oral chemotherapy medications filled through an internal health-system specialty pharmacy vs external specialty pharmacies.
    McCabe CC; Barbee MS; Watson ML; Billmeyer A; Lee CE; Rupji M; Chen Z; Haumschild R; El-Rayes B
    Am J Health Syst Pharm; 2020 Jul; 77(14):1118-1127. PubMed ID: 32537656
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disease-Modifying Therapies and Adherence in Multiple Sclerosis: Comparing Patient Self-Report with Pharmacy Records.
    McKay KA; Evans C; Fisk JD; Patten SB; Fiest K; Marrie RA; Tremlett H
    Neuroepidemiology; 2017; 48(3-4):124-130. PubMed ID: 28683461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Effect of an Integrated Health System Specialty Pharmacy on HIV Antiretroviral Therapy Adherence, Viral Suppression, and CD4 Count in an Outpatient Infectious Disease Clinic.
    Barnes E; Zhao J; Giumenta A; Johnson M
    J Manag Care Spec Pharm; 2020 Feb; 26(2):95-102. PubMed ID: 32011966
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Closing the Gap: Identifying Rates and Reasons for Nonadherence in a Specialty Population.
    Paolella D; Cherry E; Jolly JA; DeClercq J; Choi L; Zuckerman A
    J Manag Care Spec Pharm; 2019 Nov; 25(11):1282-1288. PubMed ID: 31663457
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Refill-Based Medication Use Quality Measures in Kidney Transplant Recipients: Examination of Proportion of Days Covered and Medication Possession Ratio.
    Hofmeyer BA; Look KA; Hager DR
    J Manag Care Spec Pharm; 2018 Apr; 24(4):367-372. PubMed ID: 29578851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advancing Patient Care Through Specialty Pharmacy Services in an Academic Health System.
    Bagwell A; Kelley T; Carver A; Lee JB; Newman B
    J Manag Care Spec Pharm; 2017 Aug; 23(8):815-820. PubMed ID: 28737983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A cross-sectional analysis of persistence to disease-modifying therapies in treatment naïve and experienced patients with relapsing multiple sclerosis at a health-system specialty pharmacy.
    Kozlicki MZ; Markley B; Shah NB; DeClercq J; Choi L; Zuckerman AD
    Mult Scler Relat Disord; 2022 Jul; 63():103860. PubMed ID: 35609353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary medication nonadherence rates to specialty disease-modifying antirheumatic drugs for rheumatoid arthritis within a health system specialty pharmacy.
    Petry L; Zuckerman AD; DeClercq J; Choi L; Lynch B; Saknini M
    J Manag Care Spec Pharm; 2023 Jul; 29(7):732-739. PubMed ID: 37404072
    [No Abstract]   [Full Text] [Related]  

  • 18. Adherence and persistence in patients with rheumatoid arthritis at an integrated health system specialty pharmacy.
    Peter ME; Zuckerman AD; DeClercq J; Choi L; James C; Cooper K; Choi J; Nadler M; Tanner SB
    J Manag Care Spec Pharm; 2021 Jul; 27(7):882-890. PubMed ID: 34185565
    [No Abstract]   [Full Text] [Related]  

  • 19. Medication adherence with disease modifying treatments for multiple sclerosis among US employees.
    Kleinman NL; Beren IA; Rajagopalan K; Brook RA
    J Med Econ; 2010; 13(4):633-40. PubMed ID: 20958113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapy Optimization in Multiple Sclerosis: a cohort study of therapy adherence and risk of relapse.
    Cohen BA; Coyle PK; Leist T; Oleen-Burkey MA; Schwartz M; Zwibel H
    Mult Scler Relat Disord; 2015 Jan; 4(1):75-82. PubMed ID: 25787057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.